

Daclatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)

Indications

Chronic hepatitis C

Therapeutic equivalent to glecaprevir + pibrentasvir for

Chronic hepatitis C

Therapeutic equivalent to sofosbuvir + velpatasvir for

Chronic hepatitis C

Therapeutic equivalent to sofosbuvir for

Chronic hepatitis C

Glecaprevir + pibrentasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 100 mg + 40 mg tablet

Indications

Therapeutic equivalent to daclatasvir for

Chronic hepatitis C

Chronic hepatitis C

Therapeutic equivalent to sofosbuvir + velpatasvir for

Chronic hepatitis C

Therapeutic equivalent to sofosbuvir for

Chronic hepatitis C

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 400 mg tablet

Indications

Therapeutic equivalent to daclatasvir for

Chronic hepatitis C

Therapeutic equivalent to glecaprevir + pibrentasvir for

Chronic hepatitis C

Therapeutic equivalent to sofosbuvir + velpatasvir for

Chronic hepatitis C

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 400 mg + 100 mg tablet

Indications

Therapeutic equivalent to [daclatasvir](#) for

Chronic hepatitis C

Therapeutic equivalent to [glecaprevir + pibrentasvir](#) for

Chronic hepatitis C

Chronic hepatitis C

Therapeutic equivalent to [sofosbuvir](#) for

Chronic hepatitis C